Inhibrx Biosciences (NASDAQ:INBX) Downgraded to Strong Sell Rating by Wall Street ZenMarket Beat·1 day ago, 12:06 AMINBX+0.22%MS-0.74%
Should FDA Review of Ozekibart and INBRX-106 Data Milestones Require Action From Inhibrx (INBX) Investors?Simplywall·2 days ago, 06:38 PMINBX+0.22%
Buy Rating Reaffirmed on Inhibrx Ahead of Key INBRX-106 Phase 2 Readout; $230 Price Target MaintainedTip Ranks·Aug 14 at 12:15 PMINBX+0.22%
Inhibrx Biosciences (INBX) to Announce Quarterly Earnings on WednesdayMarket Beat·Aug 5 at 07:11 AMINBX+0.22%
Inhibrx Biosciences expands Oxford Finance loan facility to USD 500 millionPUBT·Jul 16 at 08:04 AMINBX+0.22%
6 Biotech Stocks That Delivered Stunning Gains: INBX +700%, PVLA +500%, MBX +300%, ABSI +200% & Morerttnews·Jun 24 at 09:09 AMINBX+0.22%PVLA-1.70%
Inhibrx Biosciences's BLA Filing For Ozekibart Gets FDA Acceptancerttnews·Jun 15 at 08:35 AMINBX+0.22%
Stifel Nicolaus Sticks to Their Buy Rating for Inhibrx Biosciences Inc (INBX)Tip Ranks·May 15 at 07:45 AMINBX+0.22%PBE+0.58%
